Ernexa Therapeutics Inc. cash flow to debt ratio of -1.43K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Ernexa Therapeutics Inc.'s free cash flow has increased -56.47% from $-16.20M last year to $-7.05M, signaling increasing performance

Ernexa Therapeutics Inc.'s debt to equity ratio is 0.11, which means that the company's assets are healthy financed, signaling financial stability.

Ernexa Therapeutics Inc.'s debt has decreased relative to shareholder equity from 0.40 last year to 0.11 today, signaling strengthened financials

Ernexa Therapeutics Inc. has a net cash position, so leverage is healthy.

Ernexa Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Ernexa Therapeutics Inc.'s profit margin has increased (-100.00%) in the last year from -7.65K% to 0.00%, signaling increasing performance

Ernexa Therapeutics Inc.'s short-term assets of $3.13M exceed its short-term liabilities of $3.11M

Ernexa Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Ernexa Therapeutics Inc.'s return on equity of -305.85%, is lower than 15.00%, indicating bad performance

Ernexa Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Ernexa Therapeutics Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Ernexa Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Ernexa Therapeutics Inc. has negative free cash flow, indicating cash burn

Ernexa Therapeutics Inc.'s yearly earnings has increased -68.38% since last year from $-44.54M to $-14.08M, signaling increasing performance

Ernexa Therapeutics Inc.'s yearly revenue has decreased 100.00% since last year from $582.00K to $0.00, signaling decreasing performance

ROIC -328.05% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Ernexa Therapeutics Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Ernexa Therapeutics Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Ernexa Therapeutics Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Ernexa Therapeutics Inc. has insufficient data to evaluate this check.

Ernexa Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ernexa Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Ernexa Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Ernexa Therapeutics Inc. has insufficient data to evaluate this check.

Ernexa Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ernexa Therapeutics Inc. has a price-to-book ratio of 1.67x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Ernexa Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue